Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b, Muticenter Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors

NCT07878988 is registered in ClinicalTrials.gov with LTZ Therapeutics, Inc. as lead sponsor.

NCT NCT07878988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07878988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b, Muticenter Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors
Lead sponsor
LTZ Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 31, 2026
Completion date
December 31, 2031
Enrollment
152 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic solid tumor, colon cancer, colorectal cancer, epcam, solid tumor (phase i)